Tempus AI shares surged 24% after Moderna and Merck announced positive late-stage melanoma results, The Wall Street Journal reported. Tempus AI acquired Personalis for $16.25 per share (totaling $1.5 billion) on July 20. Personalis has been involved in Moderna's clinical programs and is expected to benefit from the "gold rush" in personalized cancer therapies.